STOCK TITAN
  1. Home
  2. News
  3. AADI

Aadi Bioscience Inc - AADI STOCK NEWS

Welcome to our dedicated news page for Aadi Bioscience (Ticker: AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aadi Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aadi Bioscience's position in the market.

News
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) presents new data at AACR Annual Meeting showcasing the potential of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers and overcoming resistance in non-small cell lung cancer. The data highlight synergistic effects and enhanced anti-cancer properties, supporting ongoing Phase 2 trials for endometrioid endometrial cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
conferences clinical trial
-
News
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Rhea-AI Summary
Aadi Bioscience, Inc. announces positive results from the AMPECT trial, showing efficacy and safety of nab-sirolimus in treating advanced malignant PEComa tumors of gynecologic origin. The study highlights the potential of nab-sirolimus for mTOR-driven gynecologic cancers, with consistent response rates and manageable safety profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) reports FYARRO sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023, with year-over-year growth of 21% and 60%, respectively. The company's registration-directed PRECISION1 trial for nab-sirolimus in solid tumors is on track for completion by May, with an interim analysis planned for Q3 2024. Phase 2 trials in Endometrial Cancer and Neuroendocrine Tumors are actively enrolling patients, showing promising progress in mTOR-driven cancer targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.34%
Tags
earnings
News
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) will host a conference call and webcast on March 13, 2024, to report fourth quarter and full-year 2023 financial results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences earnings
-
News
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) announces poster presentations at the 2024 AACR focusing on precision therapies for mTOR-driven cancers. Details include evaluation of nab-sirolimus in breast cancer and correlation in lung cancer xenografts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences
-
News
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) announces positive long-term efficacy and safety results from the Phase 2 AMPECT trial for nab-sirolimus in malignant PEComa patients, with a 40-month median duration of response and a >53-month median survival. The trial demonstrated a 38.7% overall response rate, including complete responses, and highlighted the potential of nab-sirolimus as an effective treatment for patients with mTOR-driven cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.82%
Tags
none
News
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) to present at the TD Cowen 44th Annual Healthcare Conference in March 2024. Dave Lennon, President and CEO, to provide a company overview on precision therapies for patients with mTOR pathway alterations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
conferences
-
News
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) presented poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, highlighting the analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database. Key findings include the prevalence of TSC1 and/or TSC2 inactivating alterations in patients with bladder, kidney, and prostate cancer, as well as the enrollment of patients in the PRECISION 1 study for solid tumors harboring these alterations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) presented real-world analysis at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, highlighting unmet medical need in GI cancer patients with TSC1/2 alterations. The analysis revealed that 1.4% of patients with GI cancers harbored at least one known or likely inactivating alteration in TSC1 or TSC2. The study also found that TSC1 and/or TSC2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers. The company is currently enrolling patients in the PRECISION 1 study (NCT05103358) for solid tumors harboring TSC1 and/or TSC2 inactivating alterations. Aadi is also presenting Trials-in-Progress (TiP) posters from its PRECISION 1 and NET clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) reports promising interim results from the PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations, demonstrating sustained tumor reductions in advanced cancer patients. The trial is expected to be completed by the end of 2024, with final data readout in early 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-56.42%
Tags
none
Stock AADI logo
Aadi Bioscience Inc

Nasdaq:AADI

AADI Rankings

#4761 Ranked by Market Cap
#5073 Ranked by Stock Gains
N/A Ranked by Dividends

AADI Stock Data

43.95M
16.00M
12.45%
52.87%
3.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Blue Ash

About AADI

aadi bioscience inc. (aadi), is a rapidly growing biopharmaceutical company focused on the development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. aadi’s lead asset, fyarrotm (sirolimus albumin-bound nanoparticles for injectable suspension), is an mtor inhibitor targeting cancers driven by genetic alterations in mtor pathway genes. supported by leading healthcare investors, aadi is currently preparing for launch of fyarro in advanced malignant pecoma, a rare type of sarcoma with no previously approved therapies. aadi’s world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing blockbuster products to market. a science-first mindset and entrepreneurial spirit is in our genes. aadi’s vision to become a leading precision oncology company is further supported by ongoing work in tumor-agnostic biomarker-driven populations (e.g., pan tumor tsc1/2 alterations) and n